History

The Story So Far

Auros's story is short and unusually legible: a 2009-founded sole-supplier specialist that took fifteen years to displace global incumbents inside Korean memory fabs, IPO'd in 2021, and is now living through its second post-IPO miss. The narrative has not drifted — overlay metrology has been the franchise since 2011 and is still 70%+ of revenue. What has drifted is the growth bridge: international expansion has been quietly walked back (the US subsidiary was approved for wind-down in December 2025), while thin-film metrology and back-end packaging — pitched since 2021 — remain "investment phase" with no announced repeat-volume orders. Management's largest forecast — "FY2023 will grow" issued after the FY2022 miss — was delivered with room to spare; the FY2026 version of that same promise is now on the table.

1. The Narrative Arc

The franchise was built before any public investor met it. Lee Jun-Woo founded the predecessor (Prodix) in March 2009 and the company qualified at Samsung Electronics and SK Hynix in 2011 — twelve years before listing. Every reporter has the same story: the OL-300n shipped in April 2011, the OL-900n flagship landed December 2020, the IPO followed in February 2021 at a ₩31,400 first-day close. The present chapter starts at that listing date. The present management chapter starts with the April 2023 conversion to a joint-CEO structure, when Choi Seong-Won was elevated alongside Lee.

The arc is mirror-image swings, not a trend. FY2021 (post-IPO), FY2023 and FY2024 were profitable; FY2022 and FY2025 were operating losses. The business has not yet demonstrated through-cycle profitability since listing — it has demonstrated cycle sensitivity inside a sole-supplier moat. The OL-900n product cycle (2020 launch → 2023-24 ramp) drove the up-leg; thin-film and back-end have not yet driven one.

2. What Management Emphasized — and Then Stopped Emphasizing

Five themes recur across the FY2022, FY2025 and August 2025 IR communications. The pattern is one of emphasis migration, not abandonment — old themes get quieter as new ones get louder.

The migrations that matter:

• Overseas expansion (US + China subsidiaries, both established July 2021) was a centerpiece of the IPO bridge and the FY2022/2023 outlook. In the FY2025 filing it survives only as a wind-down disclosure: the December 2025 board resolution to withdraw the US subsidiary was framed as "operating-cost rationalisation." That is the quietest possible burial of a four-year-old initiative.
• Thin-film metrology has gone from a pilot reference in FY2022 to the dominant growth narrative in the FY2025 filing and the August 2025 IR deck, where management calls the front-end thin-film TAM "approximately 2× the overlay TAM." The investment intensity has scaled with the rhetoric — R&D/sales jumped from 27.1% in FY2024 to 36.7% in FY2025 even as revenue fell.
• Back-end / advanced packaging (HE-900 PAD, WaPIS-30, METIS, HE-900ir) is the second growth pillar, and its language is materially more confident in August 2025 than in any prior communication — explicitly tied to HBM/AI packaging.
• Customer diversification has been the steadiest refrain — promised in FY2022 ("through customer diversification, FY2023 revenue and operating margin growth are expected"), promised again in FY2025 ("strengthening market monitoring, customer/market diversification"). The actual export mix moved the wrong way: 67% in FY2023 → 14% in FY2025.

3. Risk Evolution

The FY2022 risk disclosure was the legally-required Korean four-bucket boilerplate: market (FX, rates), credit, liquidity, capital. The FY2025 risk section keeps all four but the surrounding business description and MD&A make the real risk catalogue much richer. Either management got more candid, or the auditors made them — but the comparison is striking.

Newly visible risks (FY2025 vs FY2022): the two-vendor structure with KLA, the single-supplier sub-system concentration (stage/laser/vision = ~70% of BOM, no named suppliers), and the CapEx-cycle operating leverage that the company itself just demonstrated — revenue down 15%, gross profit down 30%, operating income swinging from +₩6.1 bn to -₩8.4 bn. The debt-to-equity ratio moved from 14.1% at FY2022 year-end to 45.2% at FY2025 year-end as bank debt funded the thin-film/back-end push through a loss-making year.

4. How They Handled Bad News

Auros has had two real "bad news" episodes since the IPO: FY2022 and FY2025. The contrast in handling is itself the story.

The wording of the recovery bridge is nearly identical across three years — new models, customer diversification, non-Korean markets. The FY2022 version produced a credible recovery in FY2023-24 driven by the OL-900n cycle. The FY2025 version leans on the same vocabulary, but the customer-diversification claim now contradicts the export-mix collapse, and the "non-Korean markets" claim sits alongside the December 2025 board approval to wind down the US subsidiary. Two of the three recovery levers are pointing in opposite directions to the words on the page.

The quarterly cadence shows the lurch in starker relief than the annual numbers. FY2024 built from a ₩6.0 bn Q1 operating loss to a ₩10.1 bn Q4 operating profit — almost the entire year's profit landed in one quarter. FY2025 mirrored that pattern in reverse: a benign first half, then a Q3 collapse (revenue down to ₩7.6 bn, single largest quarterly op-loss on record at -₩5.8 bn). Lumpiness this severe vindicates the company's own statement that it cannot meaningfully publish backlog — but it also means quarterly investors should expect repeat shocks.

5. Guidance Track Record

Auros guides loosely — there are no shipment counts, margin targets or revenue ranges of the kind US small-caps publish. The promises that matter are directional and product-level.

6 / 10. The OL-900n product cycle was promised and delivered, and the FY2022→FY2023 recovery promise was kept with margin to spare — those are the strongest credibility marks management can point to. Against that, three slower-burning promises (international expansion, thin-film commercialisation, sustained FY2024 growth into FY2025) are tracking poorly, and the December 2025 US subsidiary wind-down is a tacit admission that the 2021 IPO-era overseas plan did not work. Management's word on the front-end overlay franchise is credible; their word on the international and adjacent-product bridge has not yet earned the same trust.

6. What the Story Is Now

The story today reads:

• Core franchise intact. OL-series wafer overlay is still ~70% of revenue, still sole-Korean-domestic, still tracking the SEC/SK Hynix DRAM/NAND node roadmap. The OL-900n is on its fifth year of customer-shipment vintage; a successor cadence (one new generation roughly every 2-3 years) is overdue and visible in R&D milestones but not yet announced.
• Growth thesis pre-revenue. Thin-film metrology and back-end packaging are pitched as the next OL-900n — large TAMs (thin-film "≈2× overlay TAM" per the filing), strong R&D pipeline, but no disclosed repeat-volume orders after five years of investment. The HBM/AI packaging tailwind in the back-end portfolio is the most credible single near-term lever.
• Geography simpler. The "global metrology specialist" framing from the 2021 IPO has been edited down to "Korean memory + select export." The December 2025 US wind-down is the inflection; the August 2025 IR deck still uses the phrase "Global MI 전문 기업으로 거듭나기 위해" ("to become a global MI specialist") as the recurring tagline of every slide — the rhetoric is half a step behind the action.
• Balance sheet under more pressure. Debt-to-equity climbed from 14.1% (FY2022) to 45.2% (FY2025); cash drew down from ₩21.6 bn (FY2021) to ₩10.6 bn (FY2025). Still net-cash on absolute terms, but the trajectory is unfavourable while loss-making.
• Capital allocation tilting toward partnerships. The January 2025 Konis equity stake and the August 2025 Singapore semi stake replaced direct subsidiary expansion. This is sensible after the US wind-down but unproven.